RA Capital Management IVVD Position
Active9-Fund ConvergenceRA Capital Management held their position in Invivyd, Inc. (IVVD) in Q4 2025, holding $42.3M worth of shares across 17,119,096 shares.
The position was first reported in Q3 2025 and has been tracked across 2 quarterly 13F filings.
IVVD is a convergence signal: 9 specialist biotech funds hold this stock, suggesting high institutional conviction.
Short interest stands at 10.5% of float with 13.4 days to cover, indicating significant bearish positioning against RA Capital's long thesis.
About Invivyd, Inc.
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.
Full company profile →Short Interest
10.5%
13.4 days to cover
RA Capital Management IVVD Position History
Frequently Asked Questions
Does RA Capital Management own IVVD?
Yes. As of Q4 2025, RA Capital Management holds 17,119,096 shares of Invivyd, Inc. (IVVD) valued at $42.3M. This data comes from their SEC 13F filing.
How many hedge funds own IVVD?
9 specialist biotech hedge funds currently hold IVVD, including Perceptive Advisors, Deep Track Capital, BVF Partners and 5 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did RA Capital Management first buy IVVD?
RA Capital Management's position in IVVD was first reported in Q3 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is RA Capital Management's IVVD position increasing or decreasing?
RA Capital Management held their IVVD position unchanged in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
IVVDCompany Page →
All fund holders, insider trades, catalysts, and cash runway
RA Capital ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →